MedtechLedger currently links 38 FDA records to the applicant name Medtronic, Inc.. The collection includes 2 510(k) clearances. It includes 11 original PMA approvals. 6 entries are PMA supplements. 19 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 14, 1988 to Nov 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Device categories in this collection
Stimulator, Electrical, Implanted, For Parkinsonian Tremor; Aortic Valve, Prosthesis, Percutaneously Delivered; Pump, Infusion, Implanted, Programmable; Pulse Generator, Permanent, Implantable; Implantable Pulse Generator, Pacemaker (Non-Crt); Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass.
Changes described in PMA records
FDA approved a supplement to PMA P960009, not a new whole-system approval. The record ties S545 to the Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000), and the stated change is limited to a size change for the lead insertion tool.
The decision text also names a change in tip width dimension verification testing, but it does not supply the original measurement, the revised measurement, or any clinical rationale. The supplement type is listed as Real-Time Process, with a Process Change - Manufacturer/Sterilizer/Packager/Supplier reason.
FDA approval-order wording
approval for dimensions size change for lead insertion tool and modification to tip width dimension verification testing.
Nov 8, 2026 · Real-Time ProcessFDA lists this action as a 30-Day Notice supplement to PMA P130021/S188 for Medtronic’s Evolut FX delivery catheter system within the Evolut FX transcatheter aortic valve system. The database record frames it as a process change, not a new PMA and not a new approval of the whole system.
The only changed item described in the supplied text is “the introduction of an automated vision system for the detection of flash.” The record does not say what “flash” refers to, where the vision system is used in the manufacturing chain, or whether any device design, indication, or clinical evidence changed.
FDA approval-order wording
the introduction of an automated vision system for the detection of flash
Nov 7, 2026 · 30-Day NoticeThe FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-30 for P960009/S548, a supplement to Medtronic, Inc.'s Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense. The device category is an implanted electrical stimulator for parkinsonian tremor, classified under product code MHY in the Neurology specialty. The supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier.
The recorded scope covers three manufacturing changes: adding a new surface mount technology production line, revising the SMT process sequence so automated optical inspection follows each SMT assembly stage, and adding an equivalent solder paste inspection system plus a qualified de-paneling machine for PCBA production. This action concerns production process and equipment only; it is not an approval of the whole system, and no clinical, efficacy or labeling conclusions follow from the record. The source lists no documents, so inspection criteria, validation data and line qualification details remain unknown.
FDA approval-order wording
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
Oct 30, 2026 · 30-Day NoticeFDA lists this as supplement P860004/S465 to the SynchroMed Infusion System, Ascenda Intrathecal Catheters PMA. The decision is a 30-Day Notice for a process change, so the record describes manufacturing changes tied to the existing approved system rather than a new approval of the whole device.
The specific changes are a new surface mount technology production line, a revised SMT process sequence with automated optical inspection after each SMT assembly stage, and added solder paste inspection plus a qualified de-paneling machine for PCBA production. The source does not provide clinical data, a new indication, or device performance results; it only states the manufacturing scope of the notice.
FDA approval-order wording
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
Oct 30, 2026 · 30-Day NoticeThe FDA recorded decision OK30 on 2026-10-29 for PMA supplement P960009/S547, a 30-Day Notice submitted by Medtronic, Inc. under the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement concerns the Activa Deep Brain Stimulation Therapy System, specifically the Percept PC BrainSense DBS Neurostimulator Implantable B35200, a device in the implanted electrical stimulator category for parkinsonian tremor (product code MHY, Neurology). The action covers the listed manufacturing process changes rather than a new approval of the whole system.
The recorded statement lists six changes: enhanced operator verification of the FactoryWorks processing step and recorded battery pre-weight; pre-weight and post-weight out-of-control action plans added to Process Operation Descriptions; software and Human Machine Interface updates that automatically reject batteries with fill weights above the established final-fill reasonable limit; dedicated white work-in-progress trays for electrolyte-filled batteries; an isopropyl alcohol wipe to remove residual electrolyte before subsequent processing; and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure for Medium Rate Line 2 operators, with supervisors and engineers retaining certification responsibility. No supporting documents were included, so the basis for OK30 and any clinical implications remain unknown.
FDA approval-order wording
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
Oct 29, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.